MARK CORRIGAN
CIK 1250661 · President & CEO · last filed 2025-12-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$169.7K
Companies
10
Total Filings
60
Lifetime Open-Market Net
-$9.41M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | Director | 28,815 | $5.89 | $169.7K | -$217.3K | 8 | 2025-12-10 |
| TREVENA INC (TRVN) Delisted | Director | — | $0.01 | — | $0 | 2 | 2024-06-14 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 288 | $1.42 | $409 | -$2.0K | 6 | 2022-08-04 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 3 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Director | — | — | — | $0 | 3 | 2017-03-01 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | 21,859 | — | — | $0 | 2 | 2015-06-08 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | Director | 0 | — | — | -$400.0K | 2 | 2015-01-21 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | Director | 5,498 | — | — | -$1.17M | 9 | 2013-06-14 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | President & CEO | 87,205 | — | — | $0 | 3 | 2010-03-03 |
| SEPRACOR INC /DE/ (SEPR) Delisted | Executive VP, R&D | 70,668 | — | — | -$7.62M | 10 | 2009-10-19 |
Recent Filings · Page 2 of 6
60 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-07-30 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | +17,500 | $0 | EDGAR |
| 2021-06-04 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-20 | WVE | Grant (A) | — | $0 | EDGAR |
| 2019-09-06 | WVE | Grant (A) | — | $0 | EDGAR |
| 2019-08-01 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-08-13 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-04 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-19 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-27 | — | Other (J) | — | $0 | |
| 2017-04-11 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.